2-[2-(Pyridin-3-yl)ethynyl]-6-methyl-pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[2-(Pyridin-3-yl)ethynyl]-6-methyl-pyridine
• 英文别名: 2-Methyl-6-(2-(pyridin-3-yl)ethynyl)pyridine；2-methyl-6-(2-pyridin-3-ylethynyl)pyridine
• 化学式: C₁₃H₁₀N₂
• 分子量: 194.236
• InChiKey: KYJSGWVPWUBKGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-(三甲硅乙炔基)吡啶 在 双三苯基磷二氯化钯 氢氧化钾 、 copper(l) iodide 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 8.0h， 生成 2-[2-(Pyridin-3-yl)ethynyl]-6-methyl-pyridine
  参考文献：
  名称：

  Synthesis and receptor assay of aromatic–ethynyl–aromatic derivatives with potent mGluR5 antagonist activity

  摘要：

  Noncompetitive antagonists of the human metabotropic glutamate receptor subtype 5 (mGluR5) have been implicated as potential therapeutics for the treatment of a variety of nervous system disorders, including pain, anxiety, and drug addiction. To discover novel noncompetitive antagonists to the mGluR5, we initiated an SAR study around the known lead compounds MPEP and M-MPEP. Our results pointed out the critical role of the para position of the two aromatic rings, which leads to inactive products and permitted the discovery of potent mGluR5 antagonists (e.g., 16, 25, 28, 34 IC50 = 13.5, 11.9, 21, 15nM, respectively). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.09.042

文献信息

• Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists
  作者：Georg Jaeschke、Richard Porter、Bernd Büttelmann、Simona M. Ceccarelli、Wolfgang Guba、Bernd Kuhn、Sabine Kolczewski、Jörg Huwyler、Vincent Mutel、Jens-Uwe Peters、Theresa Ballard、Eric Prinssen、Eric Vieira、Jürgen Wichmann、Will Spooren

  DOI：10.1016/j.bmcl.2006.12.033

  日期：2007.3

  Optimization of affinity and microsomal stability led to identification of the potent, metabolically stable fenobam analog 4l. Robust in vivo efficacy of 4l was demonstrated in four different models of anxiety. Additionally, a ligand based pharmacophore alignment of fenobam and MPEP is proposed.

  亲和力和微粒体稳定性的优化导致了有效的，代谢稳定的非诺贝类似物4l的鉴定。在四种不同的焦虑模型中证明了4l具有强大的体内功效。另外，提出了基于配体的非诺贝特和MPEP的药效团比对。
• MGluR5 antagonists for the treatment of pain and anxiety
  申请人：——

  公开号：US20010056084A1

  公开（公告）日：2001-12-27

  The invention provides the use of selective mGluR5 antagonists for the treatment of pain and anxiety, and the use of mGluR antagonists for the treatment of pain, whereby analgesic effect is achieved by interaction of said antagonists primarily or predominantly at peripheral mGluR receptors.

  本发明提供了选择性 mGluR5 拮抗剂治疗疼痛和焦虑的用途，以及 mGluR 拮抗剂治疗疼痛的用途，其中镇痛效果是通过所述拮抗剂主要或主要在外周 mGluR 受体上的相互作用实现的。
• Use of mglur5 antagonists for the treatment of pruritic conditions
  申请人：——

  公开号：US20040106582A1

  公开（公告）日：2004-06-03

  The invention provides the use of mGluR5 receptor antagonists for the treatment of pruritic conditions.

  本发明提供了用于治疗瘙痒症的 mGluR5 受体拮抗剂。
• PYRIDINE DERIVATIVES
  申请人：Novartis AG

  公开号：EP0998459B1

  公开（公告）日：2008-04-23
• MGLUR5 ANTAGONISTS FOR THE TREATMENT OF PAIN AND ANXIETY
  申请人：Novartis AG

  公开号：EP1117403A1

  公开（公告）日：2001-07-25